(1 - 31 from 67
)
Pembrolizumab plus neoadjuvant chemotherapy linked to higher ...www.healio.com › hematology-oncology › breast-cancer › news › online
www.healio.com
Feb 13, · Rita Nanda. The addition of pembrolizumab to standard neoadjuvant chemotherapy significantly increased estimated pathologic complete ...
Early trial of new drug shows promise for patients with triple ...medicalxpress.com › Oncology & Cancer
medicalxpress.com
Study author Dr. Rita Nanda meets with a triple-negative breast ... options are limited to chemotherapy," said study director Rita Nanda, MD, ...
Pembrolizumab induced durable responses in metastatic triple-negative...
www.healio.com
“There are no approved targeted therapies to treat metastatic triple-negative breast cancer, and the median survival for patients with this disease is approximately 1 year,” said Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of ...
sorted by relevance / date